MCF viruses, and they mapped the responsible gene, designated Rmcff, to chromosome 5.
Although DBA/2 and other strains of mice are resistant to the development of early erythroleukemia when injected with F-MuLV, they can develop tumors (>4 mo after virus infection) that involve not only erythroid cells, but also cells of the myeloid and lymphoid lineages (6, 7, 10, 11) . There is no evidence that replication of MCF viruses is necessary for the development of these late diseases.
To better understand the genetic basis for the differences in susceptibility of mice to F-MuLV-induced early erythroleukemia and the role of MCF viruses in this disease, we studied BALB/c and DBA/2 first generation backcross mice, as well as a series of BALB/c x DBA/2 (C X 02) congenic mice.
Materials and Methods
Animals and Leukemogenicity Assays. BALB/c AnPt mice (previously designated BALB/c lr) were originally obtained from H. Andervont, NC1, in 1964. The DBA/2Pt mice were derived from DBA/2N mice. The partial C x D~ congenic stocks were originally developed to determine whether genetic markers of DBA/2 origin were linked to genes that control resistance to plasmacytomas induced by intraperitoneal injection of pristane. The methods used in deriving several of the stocks have been previously described: Pep-3 b and Idh-lb/Pep-3 b (12) ; Fv-l", Rmcff/Fv-l"/C, Rmcff, and Qa2 + (13) . The Pgm-1 b, Lyt-2 ~, C, C/a, C/d, Es-3a/Hba ~, and Igh-1 c stocks were developed by introgressively backcrossing the respective DBA/2-derived markers onto BALB/c AnPt. The phenotypes were detected by the appropriate enzymatic assays, using starch gel electrophoretic separations, or cytotoxic immunoassays. At the designated backcross generation (n), mice were mated to each other, and homozygotes for the respective markers were used to found the stock. These mice are C x D2 partial congenic stocks, and are not considered to be true congenic mice, because the number of backcrosses is <14.
All of the mice were bred under conventional conditions at an NCI contract facility (contract NO 1-CB-25584 to Litton Bionetics). Mice were infected within 72 h of birth by intraperitoneal injection of 5 x 105 XC-plaque-forming units of a stock of F-MuLV. Animals were palpated at intervals, and those judged to have enlarged spleens were killed. Data from some of the animals was obtained at autopsy. Mice were considered positive for disease if the spleen weight was >0.5 grams and the hematocrit was <30%.
Viruses and Cells. The F-MuLV used in this study was the molecularly cloned stock of F-MuLV clone 201 that has been previously described (14) . Cell-free homogenates (10%) of splenic tissue were prepared in Dulbecco-Vogt medium containing 10% fetal calf serum and clarified by centrifugation at 2,000 rpm for 10 min. NIH 3T3 cells were then infected with various dilutions of each homogenate, and the supernatants of the infected cells were monitored for virus production by the reverse transcriptase assay.
Pulse-labeling, Immune Precipitation and Polyacrylamide Gel Electrophoresis (PAGE)
Virus-infected fibroblasts or uninfected bone marrow cells were pulse-labeled with [3~S]-methionine as previously described (5, l 5). Extracts of labeled cells were immune precipitated with either goat anti-Rauscber MuLV gp70 (glycoprotein) serum (obtained from the Division of Cancer Cause and Prevention, NCI), goat anti-Moloney MCF gp70-specific serum (15) , or normal goat serum. The proteins precipitated were visualized by 7% sodium dodecyl sulfate (SDS)-PAGE.
Results

Occurrence of F-MuLV-induced Disease in BALB/c Mice Carrying Various DBA/2
Genes. BALB/c mice carrying various genes from the resistant DBA/2 mouse were injected as newborns with F-MuLV and observed for the development of early erythroleukemia (within 10 wk), as well as late erythroid and nonerythroid disease (Table I) . When resistant (BALB/c × DBA/2)FI hybrid mice are backcrossed to the susceptible BALB/c strain, 36% of the mice develop early erythroid disease. A similar incidence of early erythroleukemia was noted when resistant (NFS × DBA/2)F1 hybrid mice were backcrossed to the susceptible NFS mouse. These data suggest that more than one gene is involved in resistance of DBA/2 mice to F-MuLV-induced early erythroid disease.
To map the resistance genes in the DBA/2 mouse, we used a series of BALB/c mice partially congenic for a variety of DBA/2 genes. As shown in Table I congenic mice are backcrossed further to BALB/c (see N5 vs. N9), suggesting that BALB/c genes may favor the development o f these late F-MuLV-induced diseases.
Expression of Viral Proteins in C x D2 Congenic Mice Infected with F-MuL V.
Since the replication of MCF viruses is believed necessary for the development of the early erythroleukemia induced by F-MuLV, we examined the spleens from FMuLV-infected mice for replication of both the input F-MuLV and the generated MCF virus. This was carried out by preparing cell-free spleen homogenates from infected mice, passaging onto N I H 3T3 fibroblasts, and then examining the fibroblasts for expression of viral proteins by pulse-labeling, immune precipitation, and SDS-PAGE. As previously shown (5, 15) , the envelope proteins of FMuLV and F-MCF virus can be distinguished by size as well as by precipitation with an MCF gp70-specific antiserum. As shown in Fig. 1 and summarized in Table II , N I H 3T3 cells infected with cell-free spleen homogenates from all mice tested express high levels of the F-MuLV envelope precursor, gPr85 e"v.
T h e MCF viral envelope precursor, gPr80 ~nv, was also expressed in cells infected with the spleen homogenates from all mice susceptible to early erythroleukemia ( Fig. 1, A-F , and J) but was not expressed in cells infected with spleen homogehates from R m c f mice (Fig. 1, G-I ), indicating that MCF viruses were not replicating in the latter mice. This is consistent with previous data indicating that the Rmcp gene restricts the replication of MCF viruses (9) . Thus, BALB/c mice that are congenic for the R m c f gene and fail to replicate MCF viruses are resistant to the early erythroleukemia induced by F-MuLV. Failure to replicate MCF viruses, however, is not the only cause of resistance, since mice carrying 
a ), Fv-l" (B), Idh-lb/Pep-3 ° (C), C/d (D), C/a (E), Es-3C/Hba ~ (F), Rmcff N5 (G), Rmcp N9 (H), Rmcf/Fv-t"/C (/), and Pgm-1 ~ (J).
The homogenates were passaged onto NIH 3T3 cells, the cells were labeled 35 with [ Slmethionine, and the labeled extracts were precipitated with goat anti-Rauscher MuLV gp70 serum (lanes 1), or normal goat serum (lanes 2). Precipitated proteins were then visualized by 7% SDS-PAGE and autoradiography. * Cell-free spleen homogenates from diseased mice were passaged onto NIH 3T3 cells, and protein expression was determined by pulse-labeling, immune precipitation, and SDS-PAGE, as previously described (15) .
the DBA/2 Es-3/Hba (Fig. 1 F) and C/a (E) loci have no defect in their ability to replicate F-MuLV or MCF viruses, yet they have a considerably reduced incidence of early erythroleukemia. Thus, other DBA/2 genes in these mice must be controlling the development of erythroleukemia by a different mechanism.
Analysis of CeUs from Uninfected Mice for Viral Protein Expression. Normal cells from DBA/2 mice have previously been shown to constitutively express an MCF virus-related envelope glycoprotein that cannot be detected in cells from susceptible strains such as BALB/c (5). This protein is thought to bind to the receptor for MCF viruses and block incoming MCF viruses from infecting the cell (8).
To determine whether C X O2 congenic mice carrying the Rmcf ~ gene also constitutively express an MCF-related envelope protein, bone marrow cells from uninfected mice were examined. As shown in Fig. 2 , bone marrow cells from C X 02 mice carrying the Rmcf ~ gene express an 80 kilodaiton (kD) protein that is precipitable with an MCF gp70-specific antiserum (Fig. 2A) . No such protein could be detected in cells from other congenic mice examined (Fig. 2, B-D) , all of which replicate MCF viruses well. 
Discussion
The studies reported here establish that DBA/2 mice carry a gene on chromosome 5 at or near the Rmcflocus that plays a major role in resistance to early F-MuLV-induced erythroleukemia. The fact that this gene controls the replication of MCF viruses (9) strengthens the case for these viruses playing a crucial role in the disease, since failure to replicate these viruses results in resistance to early erythroleukemia (5 and this study). The data also indicate that additional genes on other chromosomes may contribute to resistance to F-MuLV-induced early erythroleukemia, although their mechanisms are unknown.
Normal cells from DBA/2 mice have previously been shown (5) to constitutively express an MCF-related envelope glycoprotein on the cell surface that cannot be detected on the surface of cells from susceptible strains such as BALB/c. This protein apparently binds to the receptor for MCF viruses and blocks incoming MCF viruses from infecting the cell (8) . Cells from BALB/c mice congenic for the Rmcff gene also express an MCF-related envelope glycoprotein, which is most likely responsible for the failure of MCF viruses to replicate in this strain. No such protein could be detected on the surface of cells from the other congenic mice studied, all of which replicate MCF viruses well. Thus, the Rmcf ~ gene may represent a unique viral envelope gene, or may be a regulatory locus that governs the expression of this envelope gene. It is not known whether the BALB/c mouse completely lacks the Rmcfgene or carries a different allele of this gene (RmcJ ~) that is not expressed.
There are other examples of resistance to retrovirus-induced diseases being associated with expression of endogenous envelope genes. In the mouse, replication of ecotropic virus is blocked in mice carrying the Fv-4 r allele, which is associated with the constitutive expression of an ecotropic viral envelope gene whose product blocks the replication of ecotropic viruses by viral interference (16) (17) (18) . Also, chickens expressing defective, endogenous avian leukosis viral subgroup E envelope genes were shown to be resistant to infection with subgroup E viruses (19) .
While it is clear that the Rmcf gene plays a major role in resistance of DBA/2 mice to early F-MuLV-induced erythroleukemia, the basis for resistance in C57BL mice is unclear, and may be under control of yet another resistance gene (10, 11) . These mice do not carry the Rmcf ~ gene (9), yet MCF viruses cannot be detected after infection with F-MuLV. Endogenous MCF virus-related envelope glycoproteins can be detected in cells derived from C57BL mice (5), but they are apparently not the same as the protein expressed in Rmcf" mice that blocks the receptor for MCF viruses. Perhaps C57BL mice carry a genetic defect that prevents the generation of MCF viruses or affects the number of target cells available for MCF virus infection.
Since the Rmcf ~ gene controls the replication of MCF viruses, its presence should be associated with resistance to all leukemias that are mediated by MCF viruses. The incidence of spontaneous and MCF virus-induced lymphomas in AKR mice was shown (20, 21) to be greatly reduced when the mice were crossed to DBA/2, which carries the Rmcf ~ gene. On the other hand, the Rmcf ~ gene had no effect on the incidence of pristane-induced plasmacytomas in BALB/c mice (13) , indicating that MCF viruses play no role in this disease.
Future studies on the Rmcf ~ gene will focus on cloning the gene to determine whether it represents a structural gene for a unique envelope glycoprotein or a regulatory gene that controls expression of this envelope gene.
Summary
Using a series of BALB/c mice congenic for various DBA/2 genes, we were able to establish that DBA/2 mice carry a gene on chromosome 5, at or near the Rmcf ~ locus, that plays a major role in resistance to early erythroleukemia induced by injection of Friend murine leukemia virus (F-MuLV) into newborn mice. The fact that this gene controls the replication of mink cell focus-inducing (MCF) viruses strengthens the case for these viruses playing a crucial role in the development of erythroleukemia, since failure to replicate MCF viruses results in resistance to early erythroleukemia. The expression of the Rmcp gene is correlated with the constitutive expression of an MCF virus-related envelope glycoprotein that apparently blocks the receptor for MCF viruses, preventing their spread. Thus, the Rmcf gene is either a structural gene for this unique protein, which can block the receptor for MCF viruses, or is a regulatory gene that controls expression of such a structural gene. Although the Rmcf gene is clearly involved in resistance to the early erythroleukemia induced by F-MuLV, it appears to have no effect on the late myeloid, lymphoid or erythroid diseases that appear in DBA/2 and other strains of mice after injection of F-MuLV, consistent with data indicating that replication of MCF viruses is not required for the development of these late diseases. Our studies with congenic and backcross mice also indicate that, in addition to the Rmcf" gene, other genes of DBA/2 origin may contribute to resistance to F-MuLV-induced early erythroleukemia by mechanisms other than blocking the replication of MCF viruses.
